Compare INSM & FERG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | FERG |
|---|---|---|
| Founded | 1988 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 48.5B |
| IPO Year | 2000 | N/A |
| Metric | INSM | FERG |
|---|---|---|
| Price | $156.33 | $254.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 23 | 14 |
| Target Price | $188.71 | ★ $252.64 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 02-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 1.40% |
| EPS Growth | N/A | ★ 18.63 |
| EPS | N/A | ★ 9.88 |
| Revenue | $447,022,000.00 | ★ $31,159,000,000.00 |
| Revenue This Year | $49.51 | $7.62 |
| Revenue Next Year | $134.47 | $5.38 |
| P/E Ratio | ★ N/A | $25.72 |
| Revenue Growth | ★ 30.34 | 4.92 |
| 52 Week Low | $60.40 | $146.00 |
| 52 Week High | $212.75 | $256.93 |
| Indicator | INSM | FERG |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 66.68 |
| Support Level | $153.19 | $241.97 |
| Resistance Level | $164.62 | $255.43 |
| Average True Range (ATR) | 7.67 | 5.63 |
| MACD | -0.76 | 2.47 |
| Stochastic Oscillator | 9.60 | 95.79 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Ferguson distributes plumbing and HVAC products to North American repair, maintenance and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 36,000 suppliers. Ferguson engages customers through approximately 1,800 North American branches, over the phone, online, and in residential showrooms. According to Modern Distribution Management, Ferguson is the largest plumbing distributor and second-largest HVAC distributor (next to Watsco) in North America. The firm sold its UK business in 2021 and is now solely focused on the North American market.